Bictegravir sodium, lenacapavir sodium; lenacapavir sodium
Bictegravir sodium, lenacapavir sodium; lenacapavir sodium: 1 brand, 0 generics; first approved Aug 27, 2026.
No listed patents or exclusivity: brand product(s) only.
Brand (NDA) products
- GILEAD SCIENCES INCNDA 2214432026
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 75MG BASE, EQ 50MG BASE; EQ 300MG BASE TABLET ORAL Rx —
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
All 1 application were approved in 2026.
Bictegravir sodium, lenacapavir sodium; lenacapavir sodium: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
